However, no trial was conducted to assess the efficacy and safety of the combined therapy of SGLT-2 inhibitors and ARNI in patients with HFrEF.<h4>Methods</h4>We performed a meta-analysis of the prespecified subgroups from DAPA-HF and EMPEROR-Reduced trials. This evidence concerns the gene SLC5A2 and hydrops fetalis.